Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Haematuria (positive dipstick, microscopic or visible haematuria)

Urology and andrology · Abnormal laboratory result · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In the United States, microscopic haematuria is found in 2.4% to 31.1% of healthy volunteers depending on the population studied [1].

Visible haematuria (red urine)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Dipstick positive for blood: confirm

Outside menstruation and away from a treated infection

Detailed explanation and international comparison (in French): read it in English (machine translation)

Confirmed microscopic haematuria: tests and referral

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (21)
  1. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204(4):778-786.
  2. Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135.
  3. Hicks D, Li CY. Management of macroscopic haematuria in the emergency department. Emerg Med J. 2007;24(6):385-90.
  4. Arnold MJ. Microscopic hematuria in adults: updated recommendations from the American Urological Association. Am Fam Physician. 2021;104(6):655-657 (résumé de Barocas DA et al., Microhematuria: AUA/SUFU Guideline, J Urol 2020).
  5. National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral (NG12). 2015, dernière mise à jour 2026 ; recommandations 1.6.4 à 1.6.6.
  6. O'Connor E, McVey A, Demkiw S, Lawrentschuk N, Murphy DG. Assessment and management of haematuria in the general practice setting. Aust J Gen Pract. 2021;50(7):467-71.
  7. Hansen RS, Biørn SH, Birk-Korch JB, Sheikh SP, Poulsen MH, Vinholt PJ. Prevalence of prostate cancer in men with haematuria: a systematic review and meta-analysis. BJU Int. 2023;131(5):530-9.
  8. Institut national du cancer (INCa), après avis de la HAS. Éléments d'information destinés aux médecins concernant la première prescription du PSA chez l'homme asymptomatique. Mars 2016.
  9. SPILF, comité des référentiels, avec SFGG, AFU, SFMU, SFM, SFPT, SNFMI et CNGE. Infections urinaires masculines aiguës communautaires de l'adulte (IUMACA) : mise à jour des recommandations. Diaporama du groupe recommandations, 20 juin 2026.
  10. Haute Autorité de santé. Guide du parcours de soins : maladie rénale chronique de l'adulte (MRC). Juillet 2021, mis à jour en septembre 2023.
  11. European Association of Urology (EAU). Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS), édition présentée au 41e congrès de l'EAU, Londres, 2026 ; chapitre 5 « Diagnosis » (sections 5.1 à 5.9).
  12. Nielsen M, Qaseem A ; High Value Care Task Force of the American College of Physicians. Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2016;164(7):488-97.
  13. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 3.1, juillet 2026.
  14. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204(4):778-786.
  15. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203). 2021 ; recommandations 1.1.16 à 1.1.19.
  16. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 du 2 juin 2026 : actes 5201 (ECBU) et 0219 (culot urinaire).
  17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314 (figure 48).
  18. Barocas DA, Lotan Y, Matulewicz RS, et al. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 2025;213(5):547-557.
  19. Linder BJ, Bass EJ, Mostafid H, Boorjian SA. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018;121(2):176-83.
  20. US Preventive Services Task Force. Bladder Cancer in Adults: Screening. Final Recommendation Statement, 15 août 2011 (grade I ; veille documentaire de juillet 2024).
  21. UK National Screening Committee. Bladder cancer : recommandation de dépistage, dernière revue de mars 2026.